The US Supreme Court has now heard arguments in the appeal of Teva v Sandoz from the US Court of Appeals for the Federal Circuit. This could fundamentally change how patent decisions are reviewed by the Federal Circuit and the deference given to district court rulings, says Felicia Boyd of Barnes & Thornburg.
The Supreme Court of Canada was expected to bring the Canadian law on utility more into line with other jurisdictions, but those hopes have now received a setback, as Gunars Gaikis of Smart & Biggar/Fetherstonhaugh reports.
Protecting rights related to desirable plant species is a delicate process, says Gabriel Di Blasi.
Who has legal interest in the grant of sanitary registrations for follow-on biologics? José Trigueros examines a recent case in Mexico that could have far-reaching ramifications.
Jason Rutt considers the impact AstraZeneca’s recent US pay-for-delay case will have on the industry.
AstraZeneca has had a tough few years, with a clutch of patent expiries one of the most serious of its problems. So where does it go from here? To find out, LSIPR spoke to the Anglo-Swedish pharmaceutical company’s vice president of business development about the role IP is playing in its plans for future success.
In the competitive world of cancer treatment it’s becoming ever more important to stand out from the crowd. LSIPR speaks to TapImmune’s chief executive Glynn Wilson on why he thinks the company does.
The Bay Area of California has one of the greatest concentrations of life sciences companies in the world, but its biotech community is being threatened by the seemingly unstoppable rise of large technology businesses. LSIPR spoke to Christopher Stewart, chair, and Robert Eyler, vice chair, of the new North Bay Life Science Alliance to find out how it plans to strengthen the network in the area.
Earlier this month, the first LSIPR roundtable discussion took place in a London hotel, chaired by managing editor Martin Essex, with six invited experts and deputy editor Ed Conlon taking part. We’ll be publishing a special report on the event but, to whet your appetite, here’s how the discussion began—with a lively debate on the USPTO’s guidelines on patent-eligible subject matter in the wake of the Myriad and Mayo court decisions.
Sifting through the published comments on the USPTO’s Myriad/Mayo guidelines, LSIPR found them to be overwhelmingly negative.